X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs BIOCON - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH BIOCON STERLING BIOTECH/
BIOCON
 
P/E (TTM) x -0.4 41.0 - View Chart
P/BV x 0.0 7.1 0.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 STERLING BIOTECH   BIOCON
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
BIOCON
Mar-18
STERLING BIOTECH/
BIOCON
5-Yr Chart
Click to enlarge
High Rs111,188 0.9%   
Low Rs3305 1.1%   
Sales per share (Unadj.) Rs26.868.7 39.0%  
Earnings per share (Unadj.) Rs-15.07.6 -198.1%  
Cash flow per share (Unadj.) Rs-5.514.0 -39.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs54.986.3 63.6%  
Shares outstanding (eoy) m267.87600.00 44.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.310.9 2.4%   
Avg P/E ratio x-0.598.9 -0.5%  
P/CF ratio (eoy) x-1.353.4 -2.4%  
Price / Book Value ratio x0.18.6 1.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m1,862447,900 0.4%   
No. of employees `0001.46.1 22.0%   
Total wages/salary Rs m5479,311 5.9%   
Avg. sales/employee Rs Th5,303.36,705.8 79.1%   
Avg. wages/employee Rs Th403.81,514.2 26.7%   
Avg. net profit/employee Rs Th-2,959.0736.9 -401.6%   
INCOME DATA
Net Sales Rs m7,18141,234 17.4%  
Other income Rs m432,062 2.1%   
Total revenues Rs m7,22343,296 16.7%   
Gross profit Rs m9478,291 11.4%  
Depreciation Rs m2,5433,851 66.0%   
Interest Rs m4,377615 711.7%   
Profit before tax Rs m-5,9315,887 -100.7%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,569 -122.6%   
Profit after tax Rs m-4,0074,531 -88.4%  
Gross profit margin %13.220.1 65.6%  
Effective tax rate %32.426.7 121.7%   
Net profit margin %-55.811.0 -507.8%  
BALANCE SHEET DATA
Current assets Rs m14,33541,486 34.6%   
Current liabilities Rs m49,80921,413 232.6%   
Net working cap to sales %-494.048.7 -1,014.8%  
Current ratio x0.31.9 14.9%  
Inventory Days Days40364 630.7%  
Debtors Days Days17194 181.2%  
Net fixed assets Rs m55,43250,661 109.4%   
Share capital Rs m2683,000 8.9%   
"Free" reserves Rs m13,93548,808 28.6%   
Net worth Rs m14,70151,808 28.4%   
Long term debt Rs m9,47817,898 53.0%   
Total assets Rs m73,98899,897 74.1%  
Interest coverage x-0.410.6 -3.4%   
Debt to equity ratio x0.60.3 186.6%  
Sales to assets ratio x0.10.4 23.5%   
Return on assets %0.55.2 9.7%  
Return on equity %-27.38.7 -311.6%  
Return on capital %-6.49.6 -66.7%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86012,058 15.4%   
Fx outflow Rs m257,348 0.3%   
Net fx Rs m1,8354,710 39.0%   
CASH FLOW
From Operations Rs m1,7196,621 26.0%  
From Investments Rs m-3,148-6,840 46.0%  
From Financial Activity Rs m1,426-2,397 -59.5%  
Net Cashflow Rs m-3-2,612 0.1%  

Share Holding

Indian Promoters % 33.9 40.4 83.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.0 8.4 -  
FIIs % 9.9 10.7 92.5%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 19.9 197.5%  
Shareholders   21,482 109,995 19.5%  
Pledged promoter(s) holding % 55.9 0.0 139,850.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare STERLING BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Oil Prices, Neogen Chemicals IPO, and Top Stocks in Action Today(Pre-Open)

On Tuesday, share markets in India witnessed most of the selling pressure during closing hours and ended marginally lower after a volatile day of trading.

Related Views on News

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS